Ascentage Pharma Group International (AAPG) Long-Term Investments (2023 - 2026)
Ascentage Pharma Group International (AAPG) posted quarterly Long-Term Investments of $563970.4 for Q4 2025, up 255.04% year-over-year from $158845.1 in Q4 2024, and down 12.56% quarter-over-quarter from $645000.0 in Q2 2025.
Powered by 
Analysis
Ascentage Pharma Group International (AAPG) Long-Term Investments (2023 - 2026) Analysis & Trends
Ascentage Pharma Group International's Long-Term Investments history runs 3 years deep, the most recent figure standing at $563970.4 for Q4 2025.
- In Q4 2025, Long-Term Investments rose 255.04% year-over-year to $563970.4; the TTM figure through Dec 2025 stood at $563970.4 (up 255.04% YoY), while the FY2025 annual figure was $572000.0, up 266.67% from the prior year.
- Long-Term Investments for Q4 2025 stood at $563970.4, down from $645000.0 in the prior quarter.
- The five-year high for Long-Term Investments was $2.4 million in Q4 2023, with the low at $158845.1 in Q4 2024.
- The 3-year median for Long-Term Investments is $604485.2 (2025), against an average of $932155.9.
- The sharpest annual moves came in 2024 and 2025: Long-Term Investments tumbled 93.27% in 2024, then jumped 255.04% in 2025.
- Ascentage Pharma Group International's Long-Term Investments stood at $2.4 million in 2023, then sank by 93.27% to $158845.1 in 2024, then surged by 255.04% to $563970.4 in 2025.
- Business Quant data shows AAPG's Long-Term Investments at $563970.4 in Q4 2025, $645000.0 in Q2 2025, and $158845.1 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -4.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 1.77 Bn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 372.10 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | Ascentage Pharma Group International | 1.57 Bn | 1.29 Bn | - | 4.87 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.87 Mn |
| Dec 31, 2025 | 4.66 Mn |
| Jun 30, 2025 | 4.57 Mn |
| Dec 31, 2024 | 4.55 Mn |
| Dec 31, 2023 | 2.36 Mn |